BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 29081033)

  • 1. The Presence of ALK Alterations and Clinical Relevance of Crizotinib Treatment in Pediatric Solid Tumors.
    Felkai L; Bánusz R; Kovalszky I; Sápi Z; Garami M; Papp G; Karászi K; Varga E; Csóka M
    Pathol Oncol Res; 2019 Jan; 25(1):217-224. PubMed ID: 29081033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term efficacy update of crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumour from EORTC trial 90101 CREATE.
    Schöffski P; Kubickova M; Wozniak A; Blay JY; Strauss SJ; Stacchiotti S; Switaj T; Bücklein V; Leahy MG; Italiano A; Isambert N; Debiec-Rychter M; Sciot R; Lee CJ; Speetjens FM; Nzokirantevye A; Neven A; Kasper B
    Eur J Cancer; 2021 Oct; 156():12-23. PubMed ID: 34392187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ALK inhibition in two emblematic cases of pediatric inflammatory myofibroblastic tumor: Efficacy and side effects.
    Brivio E; Zwaan CM
    Pediatr Blood Cancer; 2019 May; 66(5):e27645. PubMed ID: 30697903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Crizotinib in ALK
    Theilen TM; Soerensen J; Bochennek K; Becker M; Schwabe D; Rolle U; Klingebiel T; Lehrnbecher T
    Pediatr Blood Cancer; 2018 Apr; 65(4):. PubMed ID: 29286567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ALK immunohistochemistry positive, FISH negative NSCLC is infrequent, but associated with impaired survival following treatment with crizotinib.
    Thunnissen E; Lissenberg-Witte BI; van den Heuvel MM; Monkhorst K; Skov BG; Sørensen JB; Mellemgaard A; Dingemans AMC; Speel EJM; de Langen AJ; Hashemi SMS; Bahce I; van der Drift MA; Looijen-Salamon MG; Gosney J; Postmus PE; Samii SMS; Duplaquet F; Weynand B; Durando X; Penault-Llorca F; Finn S; Grady AO; Oz B; Akyurek N; Buettner R; Wolf J; Bubendorf L; Duin S; Marondel I; Heukamp LC; Timens W; Schuuring EMD; Pauwels P; Smit EF
    Lung Cancer; 2019 Dec; 138():13-18. PubMed ID: 31630043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anaplastic lymphoma kinase status in rhabdomyosarcomas.
    Yoshida A; Shibata T; Wakai S; Ushiku T; Tsuta K; Fukayama M; Makimoto A; Furuta K; Tsuda H
    Mod Pathol; 2013 Jun; 26(6):772-81. PubMed ID: 23307059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of ALK detection by FISH, IHC and NGS to predict benefit from crizotinib in advanced non-small-cell lung cancer.
    Lin C; Shi X; Yang S; Zhao J; He Q; Jin Y; Yu X
    Lung Cancer; 2019 May; 131():62-68. PubMed ID: 31027700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Responses to crizotinib in patients with ALK-positive lung adenocarcinoma who tested immunohistochemistry (IHC)-positive and fluorescence in situ hybridization (FISH)-negative.
    Ma D; Wang Z; Yang L; Mu X; Wang Y; Zhao X; Li J; Lin D
    Oncotarget; 2016 Sep; 7(39):64410-64420. PubMed ID: 27418132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of Crizotinib for Inflammatory Myofibroblastic Tumor with ALK mutation.
    Ogata M; Hatachi Y; Ogata T; Satake H; Imai Y; Yasui H
    Intern Med; 2019 Apr; 58(7):1029-1032. PubMed ID: 30449794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A study of ALK-positive pulmonary squamous-cell carcinoma: From diagnostic methodologies to clinical efficacy.
    Wang H; Sun L; Sang Y; Yang X; Tian G; Wang Z; Fang J; Sun W; Zhou L; Jia L; Tsao MS; Shi H; Lin D
    Lung Cancer; 2019 Apr; 130():135-142. PubMed ID: 30885334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ALK expression in rhabdomyosarcomas: correlation with histologic subtype and fusion status.
    Corao DA; Biegel JA; Coffin CM; Barr FG; Wainwright LM; Ernst LM; Choi JK; Zhang PJ; Pawel BR
    Pediatr Dev Pathol; 2009; 12(4):275-83. PubMed ID: 18788887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ALK fusion variants detection by targeted RNA-next generation sequencing and clinical responses to crizotinib in ALK-positive non-small cell lung cancer.
    McLeer-Florin A; Duruisseaux M; Pinsolle J; Dubourd S; Mondet J; Phillips Houlbracq M; Magnat N; Fauré J; Chatagnon A; de Fraipont F; Giaj Levra M; Toffart AC; Ferretti G; Hainaut P; Brambilla E; Moro-Sibilot D; Lantuejoul S
    Lung Cancer; 2018 Feb; 116():15-24. PubMed ID: 29413046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel LRRFIP1-ALK fusion in inflammatory myofibroblastic tumor of hip and response to crizotinib.
    Liu W; Duan Q; Gong L; Yang Y; Huang Z; Guo H; Niu X
    Invest New Drugs; 2021 Feb; 39(1):278-282. PubMed ID: 32915420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The tyrosine kinase inhibitor crizotinib does not have clinically meaningful activity in heavily pre-treated patients with advanced alveolar rhabdomyosarcoma with FOXO rearrangement: European Organisation for Research and Treatment of Cancer phase 2 trial 90101 'CREATE'.
    Schöffski P; Wozniak A; Leahy MG; Aamdal S; Rutkowski P; Bauer S; Richter S; Grünwald V; Debiec-Rychter M; Sciot R; Geoerger B; Marréaud S; Collette S; Nzokirantevye A; Strauss SJ
    Eur J Cancer; 2018 May; 94():156-167. PubMed ID: 29567632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Anaplastic Lymphoma Kinase Immunohistochemistry-Negative but Fluorescence In Situ Hybridization-Positive Lung Adenocarcinoma Is Resistant to Crizotinib.
    Shi R; Varella-Garcia M; Li M; Ludkovski O; Danesh A; Ng C; Pham NA; Pugh T; Shepherd FA; Tsao MS
    J Thorac Oncol; 2016 Dec; 11(12):2248-2252. PubMed ID: 27613526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How long should we continue crizotinib in ALK translocation-positive inflammatory myofibroblastic tumors? Long-term complete response with crizotinib and review of the literature.
    Alan O; Kuzhan O; Koca S; Telli TA; Basoglu T; Ercelep O; Filinte D; Sengul Y; Arikan H; Kaya S; Babacan NA; Dane F; Yumuk PF
    J Oncol Pharm Pract; 2020 Jun; 26(4):1011-1018. PubMed ID: 31615346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers.
    Sasaki T; Okuda K; Zheng W; Butrynski J; Capelletti M; Wang L; Gray NS; Wilner K; Christensen JG; Demetri G; Shapiro GI; Rodig SJ; Eck MJ; Jänne PA
    Cancer Res; 2010 Dec; 70(24):10038-43. PubMed ID: 21030459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inflammatory Myofibroblastic Tumor Driven by Novel
    Rao N; Iwenofu H; Tang B; Woyach J; Liebner DA
    J Natl Compr Canc Netw; 2018 Feb; 16(2):115-121. PubMed ID: 29439172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Benefit of crizotinib in a lung cancer patient with discordant ALK testing results.
    Grocholski S; Banerji S; Qing G; Dawe DE
    Cancer Treat Res Commun; 2018; 15():13-16. PubMed ID: 30207282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combining ALK Fluorescent In Situ Hybridization and Immunohistochemistry to Analyze Multiple Non-Small Cell Lung Carcinoma Samples per Patient Reveals Intermethod and Intersample-discrepant Results.
    Lambros L; Ginestet F; Quintin-Roué I; Le Flahec G; Uguen A
    Appl Immunohistochem Mol Morphol; 2019 Sep; 27(8):565-571. PubMed ID: 30499816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.